Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

Yee, Brittany E.; Nguyen, Nghia; Zhang, Bing; Lin, Derek; Vutien, Philip; Wong, Carrie R.; Lutchman, Glen; Nguyen, Mindie H.

doi:10.1136/bmjgast-2015-000049

Cited by 15 publications

(12 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As widely described, indeed, knowledge of HCV genotypes distribution is an important tool for monitoring the efficacy of therapies whose primary purpose is to eradicate HCV RNA, which is predicted by the achievement of a SVR that seems to be associated with improved clinical outcomes . G1 and G4 infections are associated with lower response rates and higher treatment duration in response to IFN/RBV combination therapy as compared to G2 and G3 …”

Section: Discussionmentioning

confidence: 99%

“…45 G1 and G4 infections are associated with lower response rates and higher treatment duration in response to IFN/RBV combination therapy as compared to G2 and G3. [46][47][48] Although the introduction of DAAs has solved most of adverse effects of IFN-based therapy, increasing the rates of SVR the high costs and restricted accessibility of DAA drugs are still the main drivers in the treatment decisions, especially in low-and middle-income countries. Thus, it is clear that in this context, pathogenicity and the duration and cost of treatment are still influenced by different HCV genotypes.…”

Section: Hepatitis C Virus (Hcv) Is One Of the Most Common Pathogen Inmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review

Petruzziello

Loquercio

Sabatino

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundHepatitis C virus (HCV) infection is a global health problem especially for its increasing level of mortality. Detailed knowledge of HCV genotypes prevalence has clinical relevance since the efficacy of therapies is impacted by genotypes and subtypes distribution. Moreover, HCV exhibits a great genetic variability regionally.To date, there are no published studies assessing HCV genotypes distribution in specific countries of the Mediterranean basin. The aim of this study was to review data published from 2000 to 2017 with the purpose to estimate genotypes distribution of HCV infection in nine European countries all located in the Mediterranean basin.MethodsA systematic research of peer‐reviewed journals indexed in PubMed, Scopus, and EMBASE databases selected if containing data regarding distribution of HCV genotypes in nine selected European countries (Albania, Bosnia, Croatia, France, Greece, Italy, Montenegro, Slovenia, and Spain) was performed.ResultsGenotype 1 is the most common (61.0%), ranging from 80.0% in Croatia to 46.0% in Greece, followed by genotype 3 (20.0%), varying from 38.0% in Slovenia to 7.0% and 8.0%, respectively, in Italy and in Albania and by genotype 4 (10.0%) that shows an increase of 1.1% with respect to data obtained till 2014 probably due to the increasing migrants arrivals to Southern Europe. G2, the fourth most frequent genotype (8.5%), particularly common in Italy (27.0%) and Albania (18.0%) might be probably introduced in Southern Italy as a result of Albanian campaign during Second World War and more and more increased by the migration flows from Albania to Italy in the 90s.ConclusionEpidemiology of HCV infection shows a high variability across the European countries that border the Mediterranean Sea. HCV genotyping is a relevant tool to monitor the dynamic process influenced by both evolving transmission trends and new migration flows on HCV scenario.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hepatitis C Virus (Hcv) Is One Of the Most Common Pathogen Inmentioning

confidence: 99%

Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review

Petruzziello

Loquercio

Sabatino

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…In a recent meta-analysis Yee et al, observed an SVR rate of 85% in HCV genotype 2 and genotype 3 patients who achieved EVR, while 22.3% SVR was recorded for patient without EVR. 32 Similarly, Antonov et al, established a strong correlation between EVR and SVR (p-value ≤ 0.011) in HCV 1 infected patients. 33 The findings of current study are thus compatible with previously published data establishing a positive relationship between the kinetics of the HCV RNA level early during therapy and probability of response to IFN based regimens.…”

Section: Discussionmentioning

confidence: 85%

Hepatitis C virus genotype 3a: Predictive factors associated with treatment response in patients of Peshawar.

Gul

Gul²,

Ali

et al. 2019

TPMJ

View full text Add to dashboard Cite

Hepatitis C Virus (HCV) is a flavivirus responsible for causing chronic liver diseases including cirrhosis and hepatocellular carcinoma. Identification of various patient and virus-related factors that can help predict response to antiviral therapy is extremely important in formulating the best therapeutic strategy for each patient either to continue or stop the therapy. The present study aimed to determine Sustained Virological Response (SVR) in HCV genotype 3a infected patients that received combination therapy of Sofosbuvir and Ribavirin and to investigate various factors that can help predict SVR. Study Design: Longitudinal Study Settings: Institute of basic Medical Sciences, Khyber Medical University, Peshawar (IBMS, KMU). Period: July 2016 to September 2017. Materials and Methods: Treatment response was evaluated among 100 HCV genotype 3a infected patients that received Sofosbuvir and Ribavirin therapy for 24 weeks. Various baseline parameters including hematological, biochemical and viral profiles of were recorded. HCV genotype determination was carried out by type specific nested PCR based genotyping assay. Viral load was determined at baseline, at 12 weeks for Early Virological Response (EVR) and at 24 weeks of treatment for SVR. Viral RNA quantification was carried out by Real Time PCR. Results: Out of 100 patients, SVR was observed in 83% of patients; while 17% of the chronic HCV 3a infected patients were Non-Responders (NR). Mean age of patients was low 34 ± 9.8 among patients who achieved SVR as compared to patients with non-response (41 ± 10). The 24 weeks Alanine aminotransferase (ALT) levels were significantly lower among patients with SVR (p-value ≤ 0.05). Although statistically not significant, baseline viral load was higher in NR group (p-value ≥ 0.05), than those with SVR. Association of EVR with SVR was found statistically significant (OR= 2.8, 95% CI 1.2-6.4, p-value ≤ 0.05). Conclusions: The current study indicated that pre and on-treatment monitoring of patients receiving anti-viral therapy is important for the management of patients with chronic HCV infection.

show abstract

“…A few years ago, the reference therapy was bitherapy with pegylated interferon and RBV with a sustained virological response (SVR) varying between 36.1 and 44% [5,6]. There were numerous adverse effects that sometimes led to discontinuation of treatment [6]. Currently, the treatment is based on direct-acting antiviral agents (DAAs) [7].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Eloumou¹,

Mouto²,

Bekolo³

et al. 2018

Clin Infect Immun

View full text Add to dashboard Cite

Background: There has been a revolution in the treatment of hepatitis C virus (HCV) infection since the introduction of new direct-acting antivirals agents (DAAs) in 2014. About 95% of the patients have a sustained virological response (SVR) after 12 weeks with DAAs. The aim of this study was to evaluate the SVR after 12 weeks of treatment with the combination of sofosbuvir (SOF)/ledipasvir (LDV) +/-ribavirin (RBV) among a cohort of Cameroonian HCV carriers.Methods: This was a cross-sectional study in HCV treatment centers in Cameroon health facilities in Yaounde and Douala. It focused on patients with chronic HCV of genotypes 1 and 4 treated with the SOF/ LDV +/-RBV combination for 12 weeks. The virological response after 4 and 12 weeks of treatment was determined. SVR indicating recovery was determined 12 weeks after the end of treatment (SVR12). Results:A total of 111 patients with chronic HCV were included. There was female predominance with a proportion of 58.6%. The average age of the patients was 58.8 ± 8.2 years. Genotype 1 was the most frequent with 68.5% of the cases. The SVR was 93.7% (95% CI (87.4% -97.4%)) regardless of protocol and genotype. HCV infection without cirrhosis was associated with good SVR (aOR = 0.1, 95 CI (0.1 -0.9), P = 0.02). The most common clinical adverse reaction was asthenia with 12.5% (n = 10). Conclusions:The SVR12 in Cameroonian patient infected with HCV genotypes 1 and 4 treated with the combination SOF/LDV +/-RBV was 93.7%. Cirrhosis is a factor of poor response.

show abstract

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis

Cited by 15 publications

References 89 publications

Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review

Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review

Hepatitis C virus genotype 3a: Predictive factors associated with treatment response in patients of Peshawar.

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Contact Info

Product

Resources

About